As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

After two decades of failure, novel scientific insights and technical progress are spurring meaningful innovation in the field.

The IoT can link up many facets of research—from laboratory equipment to ideas—but scientists must be ready for the questions its implementation could raise.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

From basic research in academic labs to Phase 3 clinical trials, myriad efforts are underway to divorce opioids' pain-relieving potential from their undesirable downsides.

The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.

A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.

The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.